SMARCE1 and ovarian cancer: Finally, we demonstrate that LbL NPs can quantify protease activity in response to reduction of SMARCE1 in vivo, thus resulting in a pharmacodynamic reporter of siRNA delivery and efficacy in ovarian cancer.